Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases.
Established in 2015 Intercept’s Mississauga (near Toronto) office provides medical, sales and marketing support in Canada. The team is committed to offering and maintaining high-quality service to the liver community.
Contact
Address: 90 Burnhamthorpe Road West, 14th floor, Mississauga, ON, L5B 3C3, Canada
Tel: +1 877 559 ICPT (4278)
Website https://interceptpharma.com/
Email Info-Canada@Interceptpharma.com
Looking back on three years of operations in Canada and nine months of approval of Ocaliva® for the rare non-viral liver disease PBC, Brian Canestraro, general manager of Intercept, is…
Several smaller pharmaceutical companies – Taiho, Valneva, Mallinckrodt, Théa and Intercept Pharma – have chosen to set up operations in Canada very recently, recognizing the potential for product launches and development…
See our Cookie Privacy Policy Here
